Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug spartina® put to the test in Real-World study

NCT ID NCT07262762

Disease control Sponsor: Cinnagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study is testing a drug called Spartina® (Tirzepatide) to see how well it helps people with obesity or overweight lose weight and if it is safe. About 175 adults with a BMI of 30 or higher (or 27 with a weight-related health issue) will take the drug. There is no placebo group—everyone gets the active treatment. The main goal is to see how many people lose at least 5% of their body weight.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

175 people

The number who actually took part.

Started

Nov 2025

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Primary care clinic

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female ≥18 years of age 2. Willingness for signing and having signed the informed consent form 3. BMI ≥30 kg/m² or ≥27 kg/m² with ≥1 weight-related comorbidity Exclusion Criteria: 1. Prior use of any GLP-1 agonist in the last 6 months 2. Type 1 diabetes mellitus 3. Any condition or circumstance that might pose a risk to the subject or interfere with the ability to acquire satisfactory clinical data 4. Pregnancy or breast-feeding 5. Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity / overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity / overweight

Contacts and locations

Locations

  • Akbar Aliasgarzadeh Clinic

    Tabriz, East Azerbaijan Province, Iran

  • Alireza Esteghamati clinic

    Tehran, Tehran Province, Iran

  • Behrang Motamed Clinic

    Rasht, Gilan Province, Iran

  • Dr. Mohammadhossein Dabbaghmanesh Clinic

    Shiraz, Fars, Iran

  • Farzad Hadaegh Clininc

    Tehran, Tehran Province, Iran

  • Hajieh Bibi Shahbazian Clinic

    Ahvāz, Iran

  • Imam Khomeini Hospital

    Tehran, Tehran Province, Iran

  • Iran University Endocrinology Research Center

    Tehran, Tehran Province, Iran

  • Khorshid Clinic

    Yazd, Yazd Province, Iran

  • Mansoor Siavash Dastjerdi Clinic

    Isfahan, Isfahan, Iran

  • Mohammadreza Mohajeri Tehrani Clininc

    Tehran, Tehran Province, Iran

  • Sari Diabetes Research Center

    Sari, Mazandaran, Iran

  • Seyed Mojtaba Mehrdad Clinic

    Rasht, Gilan Province, Iran

  • Shokoofeh Bonakdaran Clininc

    Mashhad, Razavi Khorasan Province, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.